Viralgen and Axovia are developing an AAV9-based gene therapy for retinal dystrophy in Bardet-Biedl Syndrome (BBS) patients. The therapy aims to stop photoreceptor cell death and vision loss using a ...

in 2014 (83), exosome-encapsulated AAV9 vectors were significantly more resistant to both ... which would be particularly detrimental for synthetic capsids that have been genetically engineered to ...

Vectors based on adeno-associated viruses (AAVs) are by far the most popular choice for in vivo gene delivery, as a result of their relatively low immunogenicity, high safety profile, broad tropism to ...

A recent study published in Cell elucidates the receptor-binding properties of the H5N1 avian influenza virus that infects cattle, revealing its potential risks to both animal and public health, ...

Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 ... Each AAV serotype exhibits unique properties ...

Laboratory for Chemistry and Life Science, Institute of Integrated Research, Institute of Science Tokyo, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan Department of Life Science ...